NCT07815067RecruitingPhase 1
A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- First submitted
- 9 Jul 2026
- Start date
- 1 Sept 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- EU CT number
- 2025-521383-35-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 320
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.